Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

RedHill Biopharma Ltd. (RDHL)

2.0436   0.004 (0.18%) 06-06 14:49
Open: 2.04 Pre. Close: 2.04
High: 2.09 Low: 2
Volume: 56,733 Market Cap: 6(M)

Technical analysis

as of: 2023-06-06 2:50:50 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 2.72     One year: 2.97
Support: Support1: 1.98    Support2: 1.64
Resistance: Resistance1: 2.33    Resistance2: 2.54
Pivot: 2.15
Moving Average: MA(5): 2.14     MA(20): 2.19
MA(100): 5.34     MA(250): 17.68
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 16.9     %D(3): 28.6
RSI: RSI(14): 33.1
52-week: High: 49.2  Low: 1.98
Average Vol(K): 3-Month: 99 (K)  10-Days: 63 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RDHL ] has closed above bottom band by 13.9%. Bollinger Bands are 86.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.17 - 2.19 2.19 - 2.2
Low: 1.95 - 1.97 1.97 - 1.98
Close: 1.99 - 2.01 2.01 - 2.03

Company Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Headline News

Tue, 06 Jun 2023
Hoth Therapeutics Shares Positive Preclinical Results for HTALZ ... - Best Stocks

Mon, 22 May 2023
RedHill Provides R&D Update - PR Newswire

Mon, 15 May 2023
RedHill Biopharma Receives NASDAQ Notification Regarding ... - InvestorsObserver

Tue, 09 May 2023
RedHill Publishes New Talicia® Data on Generic Non ... - PR Newswire

Thu, 27 Apr 2023
Premarket Mover: RedHill Biopharma Ltd (RDHL) Down 2.97% - InvestorsObserver

Mon, 17 Apr 2023
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 3 (M)
Shares Float 2 (M)
% Held by Insiders 4.3 (%)
% Held by Institutions 11.2 (%)
Shares Short 117 (K)
Shares Short P.Month 156 (K)

Stock Financials

EPS -47.46
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -20.78
Profit Margin (%) -116
Operating Margin (%) -69.4
Return on Assets (ttm) -15.8
Return on Equity (ttm) 0
Qtrly Rev. Growth -42
Gross Profit (p.s.) 0
Sales Per Share 20.94
EBITDA (p.s.) -12.4
Qtrly Earnings Growth 0
Operating Cash Flow -29 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -0.05
PEG Ratio 0
Price to Book value -0.1
Price to Sales 0.09
Price to Cash Flow -0.21

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.